On August 10, 2010, nationally known cancer researcher and clinician Craig B. Thompson was named the new President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center effective November 2, 2010.
Memorial Sloan-Kettering greatly expanded its capacity to help patients with cancer regain physical function and a sense of well-being with the opening recently of its state-of-the-art Outpatient Rehabilitation Center.
A member of the Sloan-Kettering Institute's Immunology Program and a Howard Hughes Medical Institute investigator, Alexander Rudensky is fascinated by how a specific type of white blood cells called regulatory T cells regulates our immune system.
Scheduled to open in the fall, the Memorial Sloan-Kettering Brooklyn Infusion Center will offer leading-edge chemotherapy services to current Memorial Sloan-Kettering patients who live in or near the borough.
When patients or caregivers call Memorial Sloan-Kettering's Physician Referral Service to learn about treatment options, they find compassion and expert guidance.
With the launch of a new Center for Health Policy and Outcomes, Memorial Sloan-Kettering is stepping up its efforts to develop policy that specifically applies to cancer care.
As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan-Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
A team of Memorial Sloan-Kettering clinicians and computational biologists have compiled the largest catalog to date of genetic alterations that occur in prostate cancer.
A Memorial Sloan-Kettering study now suggests that patients can receive faster and more accurate diagnoses by a method in which PET and CT are performed simultaneously and on one machine.
A multicenter study led by Memorial Sloan-Kettering researchers has answered an important question about the safety of using carbon nanotubes in medicine.